Low-Impedance 3D PEDOT:PSS Ultramicroelectrodes

The technology for producing microelectrode arrays (MEAs) has been developing since the 1970s and extracellular electrophysiological recordings have become well established in neuroscience, drug screening and cardiology. MEAs allow monitoring of long-term spiking activity of large ensembles of excitable cells noninvasively with high temporal resolution and mapping its spatial features. However, their inability to register subthreshold potentials, such as intrinsic membrane oscillations and synaptic potentials, has inspired a number of laboratories to search for alternatives to bypass the restrictions and/or increase the sensitivity of microelectrodes. In this study, we present the fabrication and in vitro experimental validation of arrays of PEDOT:PSS-coated 3D ultramicroelectrodes, with the best-reported combination of small size and low electrochemical impedance. We observed that this type of microelectrode does not alter neuronal network biological properties, improves the signal quality of extracellular recordings and exhibits higher selectivity toward single unit recordings. With fabrication processes simpler than those reported in the literature for similar electrodes, our technology is a promising tool for study of neuronal networks. \ua9 Copyright \ua9 2020 Jones, Moskalyuk, Barthold, Gut\uf6hrlein, Heusel, Schr\uf6ppel, Samba and Giugliano

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049